| Autor: |
Lally DR; New England Retina Consultants, Springfield, MA, USA. david.lally@neretina.com.; Department of Surgery, University of Massachusetts Medical School-Baystate, Springfield, MA, USA. david.lally@neretina.com., Loewenstein A; Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Arnold JJ; Marsden Eye Specialists, Parramatta, NSW, Australia., Yang YC; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK., Gedif K; Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA., Best C; Novartis Pharma AG, Basel, Switzerland., Patel H; Novartis Pharmaceuticals Corporation, East Hannover, NJ, USA.; IVERIC bio, Inc., New York, NY, USA., Tadayoni R; Department of Ophthalmology, Université de Paris, AP-HP, Lariboisière, Saint Louis and Rothschild Foundation Hospitals, Paris, France., Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA. |
Full text from SpringerLink